PubMed:32178765 / 1853-2054
Annnotations
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 0-201 | Sentence | denotes | From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126). |
T14 | 0-201 | Sentence | denotes | From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126). |
yaoziqian_800_3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T11 | 114-124 | CI | denotes | guselkumab |
T12 | 148-158 | CI | denotes | guselkumab |
T24 | 185-192 | CI | denotes | placebo |
Zierdiyeerkenaili_800_3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T12 | 114-124 | CI | denotes | guselkumab |
T13 | 148-158 | CI | denotes | guselkumab |
T21 | 185-192 | CI | denotes | placebo |